84,478 results match your criteria Lung Cancer Non-Small Cell


Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC).

Crit Rev Oncol Hematol 2020 May 5;153:102948. Epub 2020 May 5.

Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Anichstraße 35, A- 6020, Innsbruck, Austria; Tiroler Krebsforschung Institut (TKFI), Innrain 66, A-6020, Innsbruck, Austria. Electronic address:

In the highly dynamic field of advanced malignancies, biomarkers from liquid samples are urgently needed to improve treatment tailoring. However, the heterogenic data lack direct comparison of assays, vectors and relevant validations are rarely found. Therefore, we classified the available studies based on three categories: Measured vectors, applied technique and detected biomarker. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.102948DOI Listing

Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes.

Lung Cancer 2020 Jun 20;146:341-349. Epub 2020 Jun 20.

University of Groningen and University Medical Center Groningen, Departments of Pulmonary Diseases and Pathology and Medical Biology, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Electronic address:

Introduction: Non-small-cell lung cancer exhibits a range of transcriptional and epigenetic patterns that not only define distinct phenotypes, but may also govern immune related genes, which have a major impact on survival.

Methods: We used open-source RNA expression and DNA methylation data of the Cancer Genome Atlas with matched non-cancerous tissue to evaluate whether these pretreatment molecular patterns also influenced genes related to the immune system and overall survival.

Results: The distinction between lung adenocarcinoma and squamous cell carcinoma are determined by 1083 conserved methylation loci and RNA expression of 203 genes which differ for >80 % of patients between the two subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.06.008DOI Listing

Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients.

Clin Chim Acta 2020 Jul 6. Epub 2020 Jul 6.

The Fifth Medical Center, General Hospital of PLA, Beijing, 100071, China. Electronic address:

Background: Droplet digital PCR (ddPCR)-based blood detection of EGFR mutations plays significant roles in the individualized therapy of non-small-cell lung cancer (NSCLC) patients. However, a standard assay that is approved by health authorities is still lacking. Additionally, the proper application of this method in clinical settings also needs further investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2020.07.003DOI Listing

Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath-hold CT images with random survival forest: A multi-institutional study.

Med Phys 2020 Jul 9. Epub 2020 Jul 9.

Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Purpose: To predict local recurrence (LR) and distant metastasis (DM) in early-stage non-small-cell lung cancer (NSCLC) patients after stereotactic body radiotherapy (SBRT) in multiple institutions using breath-hold CT-based radiomic features with random survival forest.

Methods: A total of 573 primary early-stage NSCLC patients who underwent SBRT between January 2006 and March 2016 and met the eligibility criteria were included in this study. Patients were divided into two datasets: training (464 patients in ten institutions) and test (109 patients in one institution) dataset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.14380DOI Listing

A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

Oncology (Williston Park) 2020 Jan;34(1):21-27

Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, México.

A 40-year-old woman presented with a productive cough and shortness of breath that limited her regular activities. Her past medical history was relevant for hypertension since 2016; it is well controlled and treated with enalapril 5 mg twice daily. She also revealed a past wood smoke exposure of 2 hours per day for 10 years during her childhood. Read More

View Article

Download full-text PDF

Source
January 2020

Synchronous Bilateral Lung Cancer With Discordant Histology.

Oncology (Williston Park) 2020 Feb;34(2):55-60

Hastings Pulmonary and Sleep Clinic, Mary Lanning Healthcare, Hastings, NE.

Synchronous multiple primary lung cancer (SMPLC) is a rare occurrence affecting 0.5% to 2% of patients with lung cancer. Synchronous discordant histology with small cell and non-small cell lung carcinoma is an even less common entity. Read More

View Article

Download full-text PDF

Source
February 2020

Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?

JCO Oncol Pract 2020 Jul 9:JOP1900701. Epub 2020 Jul 9.

Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00701DOI Listing

New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials.

Expert Opin Investig Drugs 2020 Jul 9. Epub 2020 Jul 9.

Division of Medical Oncology, "S.G. Moscati" Hospital , Avellino, Italy.

Introduction: The development of immune checkpoint inhibitors (ICI) has represented a revolution in the treatment of non-small cell lung cancer (NSCLC) and has established a new standard of care for different settings. However, through adaptive changes, cancer cells can develop resistance mechanisms to these drugs, hence the necessity for novel immunotherapeutic agents.

Areas Covered: This paper explores the immunotherapeutics currently under investigation in phase I clinical trials for the treatment of NSCLC as monotherapies and combination therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2020.1793956DOI Listing

Primary prophylaxis indication for docetaxel induced febrile neutropenia in elderly patients with non-small cell lung cancer.

Cancer Invest 2020 Jul 9:1-19. Epub 2020 Jul 9.

National Hospital Organization Nagoya Medical Center.

In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10-20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357907.2020.1793350DOI Listing

Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.

Thorac Cancer 2020 Jul 8. Epub 2020 Jul 8.

Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.

Background: Immune checkpoint inhibitors (ICIs) have significant clinical efficacy in the treatment of non-small cell lung cancer (NSCLC); however, the incidence of immune-related adverse events (irAEs) of up to 50% has prevented their widespread use. With the increase in the use of ICIs alone or as combination therapy, clinicians are required to have a better understanding of irAEs and be able to manage them systematically. In this study, we aimed to assess the incidence of irAEs associated with ICIs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13541DOI Listing

ASO Author Reflections: Which of Smoking Duration or Smoking Intensity Contributes to Poor Prognosis After Resection of Non-small Cell Lung Cancer?

Ann Surg Oncol 2020 Jul 8. Epub 2020 Jul 8.

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-shi, Fukuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08852-5DOI Listing

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa064. Epub 2020 May 28.

Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Background: Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now play a vital role in patient care of this neoplasm. The authors focused on the impact of epidermal growth factor receptor mutation (EGFR-mt) status on the survival of patients after brain metastases (BMs) from NSCLC. The purpose of the study was to understand the most desirable management of BMs from NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284117PMC

Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa028. Epub 2020 Feb 28.

Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway.

Background: MRI may provide insights into longitudinal responses in the diffusivity and vascular function of the irradiated normal-appearing brain following stereotactic radiosurgery (SRS) of brain metastases.

Methods: Forty patients with brain metastases from non-small cell lung cancer ( = 26) and malignant melanoma ( = 14) received SRS (15-25 Gy). Longitudinal MRI was performed pre-SRS and at 3, 6, 9, 12, and 18 months post-SRS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212876PMC
February 2020

Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects.

Acta Pharm Sin B 2020 Jun 1;10(6):1106-1121. Epub 2019 Nov 1.

School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Platinum-based chemotherapy is used for non-small cell lung cancer (NSCLC). However, it has side effects and minimum efficacy against lung cancer metastasis. In this study, platinum-curcumin complexes were loaded into pH and redox dual-responsive nanoparticles (denoted as Pt-CUR@PSPPN) to facilitate intracellular release and synergistic anti-cancer effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apsb.2019.10.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332658PMC

Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

Am J Cancer Res 2020 1;10(6):1827-1843. Epub 2020 Jun 1.

Department of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa IA 52242, USA.

Background: Hormonal therapy using progestins, acting through the progesterone receptor (PR), is a well-established method to treat uterine endometrial hyperplasia and carcinoma. Recent population studies indicate that progestin exposure significantly reduces the incidence of ovarian, pancreatic and lung cancers in addition to endometrial cancer in women. This unexpected differentiating function of progestin in organs outside of the reproductive system led us to hypothesize that progestins/PR are protective against cancer development and progression in many tumor types. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339273PMC

Novel genetic variants of and involved in immunoregulatory interactions are associated with non-small cell lung cancer survival.

Am J Cancer Res 2020 1;10(6):1770-1784. Epub 2020 Jun 1.

Duke Cancer Institute, Duke University Medical Center Durham, NC 27710, USA.

Immunoregulatory interactions play a pivotal role in immune surveillance, recognition, and killing, particularly its internal pathway, likely playing an important role in immune escape. By using two genotyping datasets, one from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer screening trial (n = 1,185) as the discovery, and the other from Harvard Lung Cancer Susceptibility (HLCS) study (n = 984) as the validation, we evaluated associations between 4,713 genetic variants (338 genotyped and 4,375 imputed) in 60 genes involved in immunoregulatory interactions and survival of non-small cell lung cancer (NSCLC). We found that 115 SNPs were significantly associated with NSCLC overall survival in the discovery, of which four remained significant after validation by the HLCS dataset after multiple test correction by Bayesian false discovery probability. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339263PMC

The European experience.

J Thorac Dis 2020 Jun;12(6):3411-3417

Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Traditionally, pulmonary lobectomy has always been considered as the gold standard for the treatment of early stage non-small cell lung cancer (NSCLC); limited resections have been proposed in case of "compromised" patients, with relevant comorbidities. In the last years, the interest in anatomical segmentectomies among surgeons has been progressively growing, even for patients fit for lobectomy, in selected cases. In this article we debate the current trends in the treatment of early stage NSCLC around Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.01.26DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330796PMC

Novel treatment strategies for early-stage lung cancer: the oncologist's perspective.

J Thorac Dis 2020 Jun;12(6):3390-3398

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Management of early-stage non-small cell lung cancer (NSCLC) consists in multimodal treatment, including surgery, radiotherapy and chemotherapy. The mainstay of treatment is radical surgery. Definitive radiotherapy using stereotactic techniques can provide adequate local disease control, and is the treatment of choice in medically inoperable patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.02.46DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330760PMC

Uniportal VATS approach to sub-lobar anatomic resections: literature review and personal experience.

J Thorac Dis 2020 Jun;12(6):3376-3389

Thoracic Surgery Department, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai 200433, China.

Surgical scientific literature contains relatively little information regarding the surgical outcomes of anatomic sublobar resections performed with the uniportal video-assisted thoracoscopic surgery (U-VATS) technique. This paper attempts to evaluate the role of U-VATS segmentectomies in the landscape of a minimally invasive approach to the treatment of early stage non small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.01.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330759PMC

Lobectomy versus sublobar resection in patients with non-small cell lung cancer: a systematic review.

J Thorac Dis 2020 Jun;12(6):3357-3362

Thoracic Surgery Unit, University of L'Aquila, "G. Mazzini" Hospital of Teramo, Teramo, Italy.

Surgery is the gold standard treatment of lung cancer. The minimally invasive technique does not only concern access to the chest but also the limits of parenchymal resection. The study debates on the safety and oncological adequacy of sublobar resections in bronchogenic carcinoma patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.02.54DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330740PMC

Pulmonary enteric adenocarcinoma: a literature review.

Authors:
Haiyan Li Wei Cao

J Thorac Dis 2020 Jun;12(6):3217-3226

Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Pulmonary enteric adenocarcinoma (PEAC) is an extremely rare type of non-small cell lung cancer (NSCLC) with a histologic pattern that mimics metastatic colorectal cancer (MCC). The main clinical symptoms in PEAC patients are dyspnoea, coughing, hemoptysis, and chest and back pain. The first article about PEAC appeared in 1991 in the form of a case report. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-19-4171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330779PMC

Oncologic outcomes of lobectomy segmentectomy in non-small cell lung cancer with clinical T1N0M0 stage: a literature review and meta-analysis.

J Thorac Dis 2020 Jun;12(6):3178-3187

Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.

Background: Lobectomy has long been regarded as the standard treatment for operable non-small cell lung cancer (NSCLC). Recent studies suggested that segmentectomy could achieve a good prognosis for early-stage NSCLC and might be an alternative to lobectomy in this cohort. Until now, on the issue of comparison between lobectomy and segmentectomy, there remains no published randomized controlled trial (RCT), and all existing evidence is low. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-19-3802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330803PMC

Thoracoscopic segmentectomy with simple routine bronchoscopic inflation for intersegmental plane identification: short and mid-term outcomes compared with lobectomy.

J Thorac Dis 2020 Jun;12(6):3073-3084

Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland.

Background: The technical concepts of thoracoscopic segmentectomy are still evolving. In this study we present a simple bronchoscopy-based intersegmental demarcation technique with short- and mid-term outcomes compared between thoracoscopic segmentectomy and lobectomy.

Methods: All 105 consecutive patients with lung cancer intended to treat with video-assisted thoracoscopic surgery (VATS) segmentectomy were compared to 110 consecutive VATS lobectomies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-20-656DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330791PMC

Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I-IIIA non-small cell lung cancer: a propensity-matched analysis.

J Thorac Dis 2020 Jun;12(6):3043-3056

Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Background: This study aimed to evaluate the long-term survival outcomes of patients undergoing neoadjuvant chemoradiotherapy or adjuvant chemoradiotherapy for T1-4N0-1M0 disease.

Methods: Patients with pT1-4N0-1M0 between 2010 and 2015 who received pre- or postoperative (R0 resection) chemoradiotherapy were identified. The exclusion criteria included N2 or M1 disease, immunotherapy, and targeted therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-20-898DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330800PMC

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.

J Thorac Dis 2020 May;12(5):2896-2909

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

As the incidence of cancer increases worldwide there is an unmet need to understand cancer evolution to improve patient outcomes. Our growing knowledge of cancer cells' clonal expansion, heterogeneity, adaptation, and relationships within the tumor immune compartment and with the tumor microenvironment has made clear that cancer is a disease that benefits from heterogeneity and evolution. This review outlines recent knowledge of non-small cell lung cancer (NSCLC) pathogenesis and tumor progression from an evolutionary standpoint, focused on the role of oncogenic driver mutations as epidermal growth factor receptor (). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.31DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330358PMC

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors.

J Thorac Dis 2020 May;12(5):2859-2876

Department of Internal Medicine, Division of Hematology and Oncology, UC Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.

Next-generation sequencing (NGS) of tumor samples and circulating tumor DNA has revolutionized diagnostic and therapeutic strategies in lung cancer. The identification of the epidermal growth factor receptor (EGFR) oncogenic driver has translated into successful therapy of advanced lung cancer using EGFR tyrosine kinase inhibitors (TKI). Unfortunately, responses are limited by acquired mechanisms of resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.32DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330402PMC

Mechanisms of resistance to osimertinib.

J Thorac Dis 2020 May;12(5):2851-2858

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.

The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the prognosis of advanced non-small cell lung cancer (NSCLC) patients with mutations. The most common mechanism of acquired resistance to first- and second-generation EGFR TKIs is represented by the secondary mutation. Osimertinib, a third-generation TKI designed to target both EGFR sensitizing mutations and T790M, was first approved for the treatment of EGFR T790M mutation-positive NSCLC patients in progression after EGFR TKI therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.30DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330330PMC

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q.

J Thorac Dis 2020 May;12(5):2771-2780

Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

Epidermal growth factor receptor (EGFR) L718Q is a rare resistant mutation which independently leads to third-generation tyrosine kinase inhibitor (TKI) resistance. Although a few studies have examined its resistance mechanisms, no effective treatment strategy has yet been proposed for patients with this mutation. Here, we report an effective treatment strategy for the rare EGFR L718Q mutation for the first time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.29DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330377PMC

Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer.

J Thorac Dis 2020 May;12(5):2644-2653

Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan.

Background: The optimal treatment for patients with resectable non-small cell lung cancer (NSCLC) involving adjacent organs (T3 or T4) and/or cN2 remains unclear. We investigated whether or not induction chemoradiotherapy (ICRT) followed by surgery improves the survival.

Methods: We retrospectively analyzed 84 patients with NSCLC involving the adjacent organs and/or cN2 who underwent ICRT followed by surgery at our hospital from 2006 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330299PMC

Is needle biopsy a risk factor of pleural recurrence after surgery for non-small cell lung cancer?

J Thorac Dis 2020 May;12(5):2635-2643

Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.

Background: Tumor seeding, whereby malignant cells are deposited along the needle tract, is considered to be a potential hazard of needle biopsies. The aim of this study is to elucidate the relationship between needle biopsies for lung tumor, such as a preoperative computed tomography-guided needle biopsy (PCTGNB) or an intraoperative fine-needle aspiration biopsy (IFNAB), and ipsilateral pleural recurrence (PR) after lung cancer surgery.

Methods: Between 2008 and 2017, 1,047 patients with non-small cell lung cancer (NSCLC) underwent curative lung resection in our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330316PMC

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery.

J Thorac Dis 2020 May;12(5):2602-2613

Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: This study aimed to determine whether adjuvant therapy improves survival in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) after neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery.

Methods: We retrospectively reviewed 467 consecutive patients with stage IIIA-N2 NSCLC who received neoadjuvant CCRT followed by surgery between 2004 and 2013. From these, we identified 398 eligible patients and their clinical outcomes were compared according to whether adjuvant therapy was provided. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330356PMC

Tumor volume reduction evaluated by cone beam computed tomography during stereotactic body radiotherapy for early stage non-small cell lung cancer.

J Thorac Dis 2020 May;12(5):2482-2488

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.

Background: We hypothesized that significant tumor volume reduction (TVR) occurs over the course of stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer (NSCLC), and that TVR correlates with clinical outcomes.

Methods: We conducted a retrospective review of patients treated with SBRT for early stage NSCLC across two academic centers. For each patient, we contoured the tumor volume (TV) on cone beam computed tomography (CBCT) images obtained before each treatment fraction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.46DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330363PMC

Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial.

J Thorac Dis 2020 May;12(5):2450-2458

Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing 210009, China.

Background: This trial aimed to investigate the treatment response, survival profiles and treatment-related adverse events (AEs) of apatinib plus docetaxel in advanced non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR).

Methods: Thirty advanced non-squamous NSCLC patients with wild-type EGFR were recruited in this multi-center, phase II trial. All patients received apatinib (orally 500 mg, once daily until disease progression, intolerable toxicity, or death) plus docetaxel (intravenously 60 mg/m at day 1 every 3 weeks for 4-6 cycles). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.54DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330342PMC

Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review.

J Thorac Dis 2020 May;12(5):2280-2287

Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.

Background: Stereotactic ablative radiotherapy (SABR) safety and efficacy for mediastinal and hilar lymphadenopathy (MHL) is not yet established, given its potential for toxicity due to the proximity to esophagus and proximal bronchial tree (PBT). This review summarized current reported outcomes of MHL SABR.

Methods: This systematic review, based on the PRISMA guidelines, was performed using MEDLINE® (PubMed®), EMBASE and Cochrane Library databases from inception until December 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330368PMC

Spread through air spaces affects survival and recurrence of patients with clinical stage IA non-small cell lung cancer after wedge resection.

J Thorac Dis 2020 May;12(5):2247-2260

Department of Pathology, Yamagata Prefectural Central Hospital, Yamagata, Japan.

Background: Spread through air spaces (STAS) is reportedly a significant risk factor for recurrence and a prognostic factor in patients with non-small cell lung cancer (NSCLC), especially after sublobar resection. Because wedge resection (WR) is associated with insufficient margins, we hypothesized that STAS has a greater prognostic impact in patients who undergo WR compared with segmentectomy. We aimed to clarify the value of STAS as a prognostic factor in patients with NSCLC after WR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.04.47DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330349PMC

Characterising the impact of pneumonia on outcome in non-small cell lung cancer: identifying preventative strategies.

J Thorac Dis 2020 May;12(5):2236-2246

Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Background: Infections remain a part of the natural course of cancer, and lung cancer patients often present with some form of respiratory infection that can lead to their ultimate demise.

Methods: Data was gathered concerning all unplanned hospital admissions (UHAs) to our centre from three separate patient cohorts; non-small cell lung cancer (NSCLC) patients (cohort 1), "other cancer" patients (breast, prostate, colon) (cohort 2) and all non-cancer patients (cohort 3).

Results: Across the three cohorts, there were 455, 1,190 and 54,158 individual patient UHAs to our centre respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.04.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330320PMC

Frequency of exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients.

J Thorac Dis 2020 May;12(5):2172-2178

Pathology Department, Hospices Civils de Lyon, Bron, France.

Background: Mesenchymal epithelial transition receptor () alterations, including exon 14 skipping mutation, are oncogenic in non-small cell lung cancer (NSCLC) and may confer sensitivity to targeted therapy. Given the rarity and the diversity of exon 14 skipping mutations, diagnosis may be challenging on small-biopsy specimens.

Methods: Between March 2014 and May 2018, tissue samples from patients with metastatic NSCLC were analysed for exon 14 skipping mutation as part of routine practice in the Pathology Department of the Hospices Civils de Lyon, France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.04.21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330338PMC

Silencing of CD276 suppresses lung cancer progression by regulating integrin signaling.

J Thorac Dis 2020 May;12(5):2137-2145

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Background: Non-small cell lung cancer (NSCLC) is one of the cancers with the highest morbidity and mortality among the world. Studies have shown that the invasion and metastasis of tumor are biological characteristics of lung cancer, and also the main cause of treatment failure and patient death. In-depth study of lung cancer invasion related genes will help to explore the etiology of lung cancer, molecular typing and individualized treatment of lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.04.41DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330387PMC

Unexpected encounters: high prevalence of synchronous primary lung cancers in a tertiary academic center.

J Thorac Dis 2020 May;12(5):2082-2087

Department of Thoracic Surgery, Albany Medical Center, Albany, NY, USA.

Background: Accurate staging of lung cancer is paramount for directing treatment. After an internal audit suggested a higher than expected rate of synchronous multiple primary lung cancers (SMPLC), we have sought to evaluate the prevalence of SMPLC at our single, large academic center.

Methods: From January 2019 to September 2019, patients with non-small cell lung cancer who underwent surgical resection were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-19-3990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330292PMC

Prognostic impact of lymphadenectomy on outcomes of sublobar resection for non-small cell lung cancer ≤1 or >1 to 2 cm.

J Thorac Dis 2020 May;12(5):2049-2060

Department of Thoracic Surgery, Hua Mei Hospital, University of Chinese Academy of Science, Ningbo 315012, China.

Background: Lymphadenectomy is an important part of surgical treatment for non-small cell lung cancer (NSCLC). However, the prognostic impact of lymph node (LN) dissection for patients with NSCLC ≤1 and >1 to 2 cm who underwent sublobar resection is still unclear.

Methods: A group of patients numbering 7,627 with NSCLC 2 cm or less who underwent sublobar resection were identified from the Surveillance, Epidemiology, and End Results (SEER) database between January 2010 and November 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-19-3773DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330392PMC

Initial experience with uniportal video-assisted thoracoscopic surgery for the treatment of lung cancer performed by a surgeon who did not have previous experience performing multiportal thoracoscopic surgery: a single center retrospective study.

Authors:
Youngkyu Moon

J Thorac Dis 2020 May;12(5):1972-1981

Department of Thoracic & Cardiovascular Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Background: The purpose of this study was to evaluate the surgical outcome of uniportal video-assisted thoracoscopic surgery (VATS) for the treatment of non-small cell lung cancer performed by a surgeon who did not have previous experience performing open thoracotomy and multiportal VATS.

Methods: From January 2017 to December 2018, 85 patients underwent uniportal VATS anatomical pulmonary resection performed by one surgeon. The remaining 269 patients underwent multiportal VATS performed by other experienced surgeons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-20-242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330296PMC

Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers.

J Thorac Dis 2020 May;12(5):1952-1959

Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Multiple synchronous lung tumors (MSLT), particularly within a single lobe, represent a diagnostic and treatment challenge. While histologic assessment was once the only method to possibly distinguish multiple primary lung cancers, there is a growing interest in identifying unique genomic features or mutations to best characterize these processes.

Methods: In order to differentiate multiple primary lung malignancies from intrapulmonary metastases in patients with MSLT, we performed whole exome sequencing (WES) on 10 tumor samples from 4 patients with MSLT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-20-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330333PMC

Clinical significance of anemia as a prognostic factor in non-small cell lung cancer carcinoma with activating epidermal growth factor receptor mutations.

J Thorac Dis 2020 May;12(5):1895-1902

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Background: Anemia is a frequent finding in cancer patients. Pre-treatment anemia is known to be associated with poor survival after surgery or stereotactic body radiation therapy of non-small cell lung cancer (NSCLC). However, little study was conducted in NSCLC with activating epidermal growth factor receptor (EGFR) mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-19-3932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330305PMC

Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer.

J Thorac Dis 2020 May;12(5):1824-1842

Gerhard Domagk Institute of Pathology, University Hospital Muenster, Muenster, Germany.

Background: T cell infiltration in non-small cell lung cancer (NSCLC) is essential for the immunological response to malignant tissue, especially in the era of immune-checkpoint inhibition. To investigate the prognostic impact of CD4 T helper cells (T), CD8 cytotoxic (T) and FOXP3 regulatory T (T) cells in NSCLC, we performed this analysis.

Methods: By counterstaining of CD4, CD8 and FOXP3 we used immunohistochemistry on tissue microarrays (TMA) to evaluate peritumoral T cells, T cells and T cells in n=294 NSCLC patients with pTNM stage I-III disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-19-3414aDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330340PMC

Comparative of Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line.

Iran J Pharm Res 2019 ;18(3):1168-1179

Immounology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were successfully prepared and characterized by assessment of the particle size, zeta potential (ZP), polydispersity index (PDI), encapsulation efficiency (EE), and drug loading (DL). DAPI staining and Flow cytometry techniques were employed to probe anticancer activities of the optimal formulations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22037/ijpr.2019.1100775DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934956PMC
January 2019

Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.

Sci Rep 2020 Jul 8;10(1):11236. Epub 2020 Jul 8.

Department of Respiratory Medicine, The Second Hospital of Jilin University, 218 Ziqiang Street, Nanguan District, Changchun, 130041, Jilin, People's Republic of China.

Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) have shown promise against non-small cell lung cancers (NSCLCs) in clinics but the utility is often short-lived because of T790M mutations in EGFR that help evade TKIs' action. Osimertinib is the third and latest generation TKI that targets EGFRs with T790M mutations. However, there are already reports on acquired resistance against Osimertinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67908-4DOI Listing

Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series.

Sci Rep 2020 Jul 8;10(1):11201. Epub 2020 Jul 8.

Academic Department of Radiation Oncology, Centre Oscar Lambret, 59020, Lille Cedex, France.

Stereotactic radiotherapy (SRT) of brain metastases (BM) results are often reported in the heterogeneous primitive population. Here, we report our experience in consecutively treated patients who underwent SRT alone for BM from non-small cell lung cancer (NSCLC). This retrospective analysis included consecutive patients with no history of cerebral treatment who underwent Cyberknife™ SRT for BM from NSCLC in our institution from 2007 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-68209-6DOI Listing

Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).

Clin Lung Cancer 2020 May 23. Epub 2020 May 23.

Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.

Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits EGFR activating and EGFR T790M resistance mutations. Osimertinib was found to be more effective than first-generation EGFR-TKIs in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) harboring EGFR-positive mutations in a prior phase III trial. Osimertinib is, therefore, one of the most important standard therapies for EGFR mutation-positive patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.023DOI Listing